ArticleMolecular biology reports2025
Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agent.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing prevalence of highly antibiotic-resistant pathogen Pseudomonas aeruginosa, necessitates the exploration of novel therapeutic alternatives. This study aimed to isolate and characterize a bacteriophage with potential applications against P. aeruginosa wound infection. METHODS AND
resultsThe lytic phage ZAM-Pa99 was isolated from hospital sewage and subjected to comprehensive analysis, including morphological characterization, physicochemical properties, growth dynamics, biofilm degradation, genome sequencing, and bioinformatics analysis. ZAM-Pa99 was classified as a newly characterized isolate within the Pbunavirus genus, demonstrating a broad lytic host range (80% efficacy) against the tested clinical strains. This result aligns with in silico host-range predictions, which reflect the high sequence similarity of its receptor-binding proteins with those of relatedPbunavirus phages. Genomic analysis (65,139 bp) was crucial for identifying its therapeutic safety profile, confirming the absence of virulence factors or antimicrobial resistance genes. Importantly, multi-tool proteomic analysis resolved a canonical lysis cassette including a confirmed endolysin, a holin candidate and an identified tailspike-like receptor-binding protein with strong putative depolymerase activity. This mechanism correlated with functional results: ZAM-Pa99 achieved up to 95% degradation of 1-day-old P. aeruginosa biofilms, maintaining high efficacy against 3- and 5-day-old mature structures, results that were quantified and visually confirmed.
conclusionZAM-Pa99's promising characteristics, including its broad host range, biofilm-degrading ability, and lack of harmful genes, make it a promising candidate for phage-based therapy against P. aeruginosa infections. These findings contribute to a growing body of evidence supporting the potential of bacteriophages as valuable nature's weapons for combating antibiotic-resistant pathogens.
Indexed as
Identifiers
41369844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.